



Express Mail No.: EV335857137US

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application of: Siegal et al.  
Serial No.: 10/067,146

Confirmation No.: 7266  
Group Art Unit: 1636

Filed: February 4, 2002

Examiner: Kaushal, Sumesh

For: TYPE I INTERFERON-  
PRODUCING CELLS AND USES  
THEREOF

Attorney Docket No.: 10034-004

RECEIVED  
OCT 10 2003  
TECH CENTER 1600

INFORMATION DISCLOSURE STATEMENT UNDER 37 C.F.R. §1.97 & §1.56

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Sir:

In accordance with the duty of disclosure imposed by 37 C.F.R. §1.56 to inform the Patent and Trademark Office of all references coming to the attention of Applicants or their attorneys which are or may be related to patentability of the claimed invention, Applicants hereby direct the Examiner's attention to references **A01**, and **C01 to C62**, which are listed on the accompanying revised PTO Form 1449.

Copies of the references **A01**, and **C01 to C62**, are submitted herewith. Applicants respectfully request that the Examiner review the foregoing references and that the references be made of record in the file history of the application.

Identification of the listed references is not to be construed an admission by Applicants or their attorneys that such references are available as "prior art" against the subject application.

Pursuant to 37 C.F.R. § 1.97(b), it is estimated that no fee is due. However, if a fee is deemed to be due, please charge the required fee to Pennie & Edmonds LLP Deposit Account No. 16-1150. A duplicate of this sheet is enclosed for accounting purposes.

Respectfully submitted,

Date October 6, 2003

Laura A. Coruzzi  
Laura A. Coruzzi (Reg. No.)

PENNIE & EDMONDS LLP  
1155 Avenue of the Americas  
New York, New York 10036-2711  
(212) 790-9090

By: Jennifer D. Chedoke  
Reg No. 46,617  
NY2: 1469793.1

OCT 06 2003

Express Mail No.: EV335857137US

Sheet 1 of 2

## LIST OF REFERENCES CITED BY APPLICANT

(Use several sheets if necessary)

ATTY DOCKET NO.

10034-004-999

APPLICATION NO

10/067,146

APPLICANT

Siegal et al.

FILING DATE

February 4, 2002

GROUP

1636

## U.S. PATENT DOCUMENTS

*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	A01	5,676,942	10/14/97	Testa et al.			

## FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION
							YES NO

## OTHER REFERENCES (Including Author, Title, Date, Pertinent Pages, Etc.)

C01	Abb et al., 1983, "Phenotype of human alpha-interferon producing leucocytes identified by monoclonal antibodies," Clin Exp Immunol. 52(1):179-84
C02	Autran et al., 1997, "Positive effects of combined antiretroviral therapy on CD4+ T cell homeostasis and function in advanced HIV disease," Science 277(5322):112-6
C03	Bandyopadhyay et al., 1986, "Requirement for HLA-DR+ accessory cells in natural killing of cytomegalovirus-infected fibroblasts," J Exp Med. 164(1):180-95
C04	Brinkmann et al., 1993, "Interferon alpha increases the frequency of interferon gamma-producing human CD4+ T cells," J Exp Med. 178(5):1655-63
C05	Bubenik, 1996, "Cytokine Gene-Modified Vaccines in the Therapy of Cancer," Pharmacol. Ther. 69(1):1-14
C06	Cederblad et al., 1991, "Interferons and the colony-stimulating factors IL-3 and GM-CSF enhance the IFN-alpha response in human blood leucocytes induced by herpes simplex virus," Scand J Immunol. 1991 Nov;34(5):549-55
C07	Chehimi et al., 1989, "Dendritic cells and IFN-alpha-producing cells are two functionally distinct non-B, non-monocytic HLA-DR+ cell subsets in human peripheral blood," Immunology 68(4):488-90
C08	Clerici et al., 1994, "The Th1-Th2 hypothesis of HIV infection: new insights," Immunol Today 15(12):575-81 Review
C09	Dong et al., 1999, Cancer Res. 59:872-879
C10	Eck et al., 1996, "Gene-Based Therapy," Pharmacological Basis of Therapeutics, Chapter 5: 77-101
C11	Empson et al., 1999, "Atopy, anergic status, and cytokine expression in HIV-infected subjects," J Allergy Clin Immunol. 103(5 Pt 1):833-42
C12	Feldman et al., 1995, J. Leuk. Biol. 57:214-220
C13	Feldman et al., 1994, Virology 204:1-7
C14	Feldman et al., 1990, J. Interferon Res. 10:435-446
C15	Ferbas et al., 1995, Clin. Diagn. Lab. Immunol. 2:138-142
C16	Ferbas et al., 1994, J. Immunol. 152:4649-4662
C17	Fitzgerald-Bocarsly, 1993, Pharmacol. Ther. 60:39-62
C18	Fitzgerald-Bocarsly, 1988, J. Leuk. Biol. 43:323-334
C19	Ghanekar et al., 1996, J. Immunol. 157:4028-4036
C20	Grouard et al., 1997, J. Exp. Med. 185:1101-1111 (or Grouard)
C21	Harrison et al., 1997, J. Immunol. 158:459-463
C22	Howell et al., 1994, Clin. Immunol. Immunopathol. 71(2):223-230

NY2: 1467663.1

C23	Isaacs et al., 1957, Proc. R. Soc. London 147:25B
C24	Kirchner et al., 1979, Immunobiology 156:65-75
C25	Komanduri et al., 1998, Nat. Med. 4:953-956
C26	Kostense et al., 1998, AIDS 12:F235-240
C27	Ledergerber et al., 1999, J. Amer. Med. Assn. 282:2220-2226
C28	Lederman et al., 1998, J. Inf. Dis. 178:70-79
C29	Ledley, 1991, Human Gene Therapy 2:77-83
C30	Leigh et al., 1998, J. Acquir. Immune Ded. Syndr. Hum. Retrovirol. 19:373-380
C31	Lopez et al., 1983, J. Inf. Dis. 148:962-966
C32	Marrack et al., 1999, J. Exp. Med. 189:52
C33	Milone et al., 1998, J. Immunol. 161:2391-2399
C34	Mocroft et al., 1998, Lancet 352:1725-1730
C35	O'Doherty et al., 1994, Immunology 82:487
C36	O'Doherty et al., 1993, J. Exp. Med. 178:1067
C37	Olweus et al., 1997, PNAS USA 94:125551
C38	Pakker et al., 1998, Nat. Med. 4:208-214
C39	Palella et al., 1998, N. Engl. J. Med. 338:853-860
C40	Parronchi et al., 1996, Eur. J. Immunol. 26:697-703
C41	Payvandi et al., 1998, J. Immunol. 160:5861-5868
C42	Perussia et al., 1985, Nat. Immunol. Cell Growth Regul. 4:120-137
C43	Peter et al., 1980, Eur. J. Immunol. 10:547-555
C44	Pontesilli et al., 1999, Immunol. Lett. 66:213-217
C45	Powderly et al., 1998, J. Amer. Med. Assoc. 280:72-77
C46	Qin et al., 1998, PNAS 95:14411-14416
C47	Rappocciolo et al., 1989, J. Clin. Microbiol. 27:41-48
C48	Rissoan et al., 1999, Science 283:1183-1186
C49	Rogge et al., 1998, J. Immunol. 161:6567-6574
C50	Sandberg et al., 1991, Scan. J. Immunol. 34:565-576
C51	Sandberg et al., 1990, J. Immunol. 145:1015-1020
C52	Sanhadji et al., 1997, AIDS 11:977-986
C53	Schneider et al., 1999, Lancet 353:201-203
C54	Shodell, M., FP Siegal: abstract submitted, FASEB AAI/CIS Congress, Seattle, WA, May, 2000
C55	Siegal et al., 1999, Science 284:1835-1837
C56	Siegal et al., 1994, Leukemia 8:1474-1479
C57	Siegal et al., 1986, J. Clin. Invest. 78:115-123
C58	Starr et al., 1993, Acv. Exp. Med. Biol. 329:173-178
C59	Sun et al., 1998, J. Exp. Med. 188:2335
C60	Svensson et al., 1996, J. Interferon Cytok. Res. 16:7-16
C61	Svensson et al., 1996, Scan. J. Immunol. 44:164-172
C62	Viellard et al., 1997, PNAS 94:11595-11600

EXAMINER

DATE CONSIDERED

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.